Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 5/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369728 | 0.98 | GPR183 (0.44) | GPR183PTGS2ADORA2AKCNH2ACACB | |
| SCHEMBL369362 | 0.97 | GPR183 (0.43) | GPR183PTGS2KCNH2ACACBALDH1A1 | |
| SCHEMBL1390360 | 0.82 | GPR183 (0.38) | GPR183PTGS2ADORA2AACACB | |
| SCHEMBL369245 | 0.77 | SMN1; SMN2 (0.40) | PTGS2ACACBALDH1A1SMN1; SMN2HTT | |
| SCHEMBL368252 | 0.76 | GPR183 (0.41) | GPR183KCNH2ACACBALDH1A1SMN1; SMN2 | |
| SCHEMBL369699 | 0.76 | GPR183 (0.41) | GPR183KCNH2ACACBALDH1A1SMN1; SMN2 | |
| SCHEMBL369190 | 0.76 | GPR183 (0.41) | GPR183KCNH2ACACBALDH1A1SMN1; SMN2 | |
| SCHEMBL1390305 | 0.75 | GPR183 (0.40) | GPR183ACACBALDH1A1SMN1; SMN2 | |
| SCHEMBL369181 | 0.74 | GPR183 (0.44) | GPR183KCNH2ALDH1A1 | |
| SCHEMBL369863 | 0.72 | SMN1; SMN2 (0.40) | GPR183ALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | GPR183 80/4885PTGS2 259/4885ADORA2A 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.